Not Tagged
day one biopharmaceutical
['$dawn']
$dawn orr of 67% and clinical benefit rate (cbr) of 93% in 69 heavily pretreated rano-hgg evaluable patients.
expects to complete rolling nda submission in october. #asco23
Investor/trader focused primarily in the biopharma sector. 
Tweets are not investment advice and are not recommendations of any kind.